ClinicalTrials.gov
ClinicalTrials.gov Menu

Questionnaire and Laboratory Data on Vitiligo Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01206374
Recruitment Status : Completed
First Posted : September 21, 2010
Last Update Posted : May 25, 2015
Sponsor:
Collaborator:
Beth Israel Medical Center
Information provided by (Responsible Party):
St. Luke's-Roosevelt Hospital Center

Brief Summary:
Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals). While genes have been identified that are thought to be required for development of vitiligo, only 5-10% of relatives develop disease. The triggers for disease onset have not yet been identified. The intent of this study is to research trends in laboratory data, social and medical history that may be contributory to vitiligo onset, location of disease, course of illness and response to therapy.

Condition or disease
Vitiligo Vulgaris

Detailed Description:
Patients who participate in this study will be asked to complete a survey and have blood/ laboratory testing performed that relates or may relate to the diagnosis of vitiligo.

Study Type : Observational
Actual Enrollment : 57 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris
Study Start Date : August 2010
Actual Primary Completion Date : October 2010
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitiligo




Primary Outcome Measures :
  1. Quality of life disturbances in people with vitiligo [ Time Frame: point prevalence ]
    dermatology life quality indices were you used and correlated with location of disease


Secondary Outcome Measures :
  1. self-reporting of vitiligo disease symptoms and history [ Time Frame: single survey ]
    Correlation of the patient survey response with chart documentation was performed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
All patients willing to sign consent, complete questionnaire and/ or laboratory studies.
Criteria

Inclusion Criteria:

  • Diagnosis of Vitiligo Vulgaris
  • Ability to sign consent

Exclusion Criteria:

  • Pregnant
  • Inability to sign consent
  • Inability to complete questionnaire

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01206374


Locations
United States, New York
Department of Dermatology, Beth Israel Medical Center
New York, New York, United States, 10003
Department of Dermatology, St. Luke's-Roosevelt Hospital Center
New York, New York, United States, 10025
Sponsors and Collaborators
St. Luke's-Roosevelt Hospital Center
Beth Israel Medical Center
Investigators
Principal Investigator: Nanette Silverberg, MD StLukesNY